KRAS mutation promotes the autonomous expression of type I cytokine receptor complexes (IL2r-IL4r and IL2r-IL13r1) in cancer cells, which can then bind to and take up cytokine growth signals (IL4 or IL13) released by Th2 cells in the microenvironment 121. Here, KRAS is linked to cancer.